ALLR

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. It is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.

Wall Street analysts forecast ALLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALLR is 9.25 USD with a low forecast of 9.25 USD and a high forecast of 9.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Allarity Therapeutics Inc revenue for the last quarter amounts to -2.52M USD, decreased -3.52 % YoY.

Allarity Therapeutics Inc. EPS for the last quarter amounts to USD, decreased % YoY.

Allarity Therapeutics Inc (ALLR) has 6 emplpoyees as of January 10 2026.

Today ALLR has the market capitalization of 18.79M USD.